Elite Pharmaceuticals, Inc. (ELTP)
OTCMKTS · Delayed Price · Currency is USD
0.3990
+0.0290 (7.84%)
Jul 16, 2026, 3:59 PM EST

Elite Pharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Apr - Mar.
Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Net Income
44.87-4.3120.113.568.9
Depreciation & Amortization
2.022.121.521.331.42
Other Amortization
0.010.01-0.010.01
Loss (Gain) From Sale of Assets
-0.12---
Asset Writedown & Restructuring Costs
0.851.6-0.29-
Stock-Based Compensation
0.180.236.750.580.78
Provision & Write-off of Bad Debts
1.050.150.24--
Other Operating Activities
2.6922.7-19.96-0.43-3.6
Change in Accounts Receivable
-31.56-9.9-16.6-0.040.44
Change in Inventory
-5.02-3.31-3.38-2.81-1.73
Change in Accounts Payable
3.10.240.021.340.31
Change in Unearned Revenue
-0.01-0.01-0.01--0.01
Change in Other Net Operating Assets
5.57-2.188.07-0.5-0.02
Operating Cash Flow
23.757.46-3.243.346.51
Operating Cash Flow Growth
218.52%---48.70%103.78%
Capital Expenditures
-0.93-1.63-0.81-5.74-0.5
Sale of Property, Plant & Equipment
-0.13---
Sale (Purchase) of Intangibles
--0.9---
Investing Cash Flow
-0.93-2.4-0.81-5.74-0.5
Short-Term Debt Issued
--4--
Long-Term Debt Issued
---14.44-
Total Debt Issued
--414.44-
Short-Term Debt Repaid
-4----
Long-Term Debt Repaid
-0.64-0.85-0.66-12.74-0.67
Total Debt Repaid
-4.64-0.85-0.66-12.74-0.67
Net Debt Issued (Repaid)
-4.64-0.853.341.7-0.67
Issuance of Common Stock
0.320.02---
Financing Cash Flow
-4.32-0.833.341.7-0.67
Net Cash Flow
18.54.23-0.71-0.75.34
Free Cash Flow
22.825.83-4.04-2.46.01
Free Cash Flow Growth
291.43%---109.85%
Free Cash Flow Margin
15.33%6.94%-7.14%-7.02%18.63%
Free Cash Flow Per Share
0.020.01-0.00-0.000.01
Cash Interest Paid
0.250.670.121.10.18
Cash Income Tax Paid
1.150.610.290.42-
Levered Free Cash Flow
5.87-2.18-4.87-4.553.6
Unlevered Free Cash Flow
6.1-1.71-4.5-3.873.71
Change in Working Capital
-27.92-15.17-11.89-2.01-1.01